Claims
- 1. A purified protein comprising a polypeptide selected from:
a) an amino acid sequence of SEQ ID NO: 1; b) a biologically active portion of SEQ ID NO: 1; c) an antigenic epitope of SEQ ID NO: 1, and d) an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1.
- 2. An isolated cDNA comprising a polynucleotide encoding a protein having the amino acid sequence of SEQ ID NO: 1 or a complement of the cDNA.
- 3. An isolated cDNA comprising a polynucleotide having a nucleic acid sequence of SEQ ID NO: 2 or a complement of SEQ ID NO: 2.
- 4. The fragment of claim 3 extending from about nucleotide G1 to about nucleotide T332, from about nucleotide C479 to about nucleotide C847, from about nucleotide G500 to about nucleotide G792, and from about nucleotide G1083 to about nucleotide G1226 of SEQ ID NO: 2 or the complements thereof.
- 5. The oligonucleotide of claim 3 extending from about nucleotide C512 to about nucleotide G575 of SEQ ID NO: 2 or the complement thereof.
- 6. A composition comprising the cDNA of claim 2 and a labeling moiety.
- 7. A substrate upon which the cDNA of claim 2 is immobilized.
- 8. A vector comprising the cDNA of claim 2.
- 9. A host cell comprising the vector of claim 9.
- 10. A method for using a cDNA to produce a protein, the method comprising:
a) culturing the host cell of claim 10 under conditions for protein expression; and b) recovering the protein from the host cell culture.
- 11. A composition comprising the cDNA of claim 3 and a labeling moiety.
- 12. A method for using a cDNA to detect expression of a nucleic acid in a sample comprising:
a) hybridizing the composition of claim 6 to nucleic acids of the sample under conditions to form at least one hybridization complex; and b) detecting hybridization complex formation, wherein complex formation indicates expression of the nucleic acid in the sample.
- 13. The method of claim 12 further comprising amplifying the nucleic acids of the sample prior to hybridization.
- 14. The method of claim 12 wherein the composition is attached to a substrate.
- 15. The method of claim 12 wherein the sample is from colon, liver, lung, ovary, and prostate.
- 16. The method of claim 12 wherein complex formation is compared to standards and is diagnostic of colon or lung cancer.
- 17. A method of using a cDNA to screen a plurality of molecules or compounds, the method comprising:
a) combining the cDNA of claim 2 with a plurality of molecules or compounds under conditions to allow specific binding; and b) detecting specific binding, thereby identifying a molecule or compound which specifically binds the cDNA.
- 18. The method of claim 17 wherein the molecules or compounds are selected from antisense molecules, artificial chromosome constructions, branched nucleic acids, DNA molecules, enhancers, peptide nucleic acids, peptides, proteins, repressors, RNA molecules, and transcription factors.
- 19. A method for using a cDNA to assess efficacy of a molecule or compound, the method comprising:
a) treating a sample containing nucleic acids with the molecule or compound; b) hybridizing the nucleic acids of the sample with the cDNA of claim 2 under conditions for hybridization complex formation; c) determining the amount of complex formation; and d) comparing the amount of complex formation in the treated sample with the amount of complex formation in an untreated sample, wherein a difference in complex formation indicates efficacy of the molecule or compound.
- 20. A method for using a cDNA to assess toxicity of a molecule or compound, the method comprising:
a) treating a sample containing nucleic acids with the molecule or compound; b) hybridizing the nucleic acids with the cDNA of claim 2 under conditions for hybridization complex formation; c) determining the amount of complex formation; and d) comparing the amount of complex formation in the treated sample with the amount of complex formation in an untreated sample, wherein a difference in complex formation indicates toxicity of the molecule or compound.
- 21. An oligopeptide comprising residue D125 to about residue A140 of SEQ ID NO: 1.
- 22. A composition comprising the protein of claim 1 and a labeling moiety.
- 23. A composition comprising the protein of claim 1 and a pharmaceutical carrier.
- 24. A substrate upon which the protein of claim 1 is immobilized.
- 25. An array element comprising the protein of claim 1.
- 26. A method for detecting expression of a protein having the amino acid sequence of SEQ ID NO: 1 in a sample, the method comprising:
a) performing an assay to determine the amount of the protein of claim 1 in a sample; and b) comparing the amount of protein to standards, thereby detecting expression of the protein in the sample.
- 27. The method of claim 26 wherein the assay is selected from two-dimensional polyacrylamide electrophoresis, western analysis, mass spectrophotometry, enzyme-linked immunosorbent assay, radioimmunoassay, fluorescence activated cell sorting, and array technology.
- 28. The method of claim 26 wherein the sample is from colon, liver, lung, ovary, and prostate.
- 29. The method of claim 26 wherein the protein is differentially expressed when compared with the standard and is diagnostic of colon or lung cancer.
- 30. A method for using a protein to screen a plurality of molecules and compounds to identify at least one ligand, the method comprising:
a) combining the protein of claim 1 with a plurality of molecules and compounds under conditions to allow specific binding; and b) detecting specific binding, thereby identifying a ligand that specifically binds the protein.
- 31. The method of claim 30 wherein the molecules and compounds are selected from agonists, antagonists, bispecific molecules, DNA molecules, small drug molecules, immunoglobulins, inhibitors, mimetics, multispecific molecules, peptides, peptide nucleic acids, pharmaceutical agent, proteins, and RNA molecules.
- 32. A method for using a protein to identify an antibody that specifically binds the protein having the amino acid sequence of SEQ ID NO: 1 comprising:
a) contacting a plurality of antibodies with the protein of claim 1 under conditions to allow specific binding, and b) detecting specific binding between an antibody and the protein, thereby identifying an antibody that specifically binds the protein.
- 33. The method of claim 32, wherein the plurality of antibodies are selected from a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a recombinant antibody, a humanized antibody, a single chain antibody, a Fab fragment, an F(ab′)2 fragment, an Fv fragment; and an antibody-peptide fusion protein.
- 34. A method of using a protein to prepare and purify a polyclonal antibody comprising:
a) immunizing a animal with a protein of claim 1 under conditions to elicit an antibody response; b) isolating animal antibodies; c) attaching the protein to a substrate; d) contacting the substrate with isolated antibodies under conditions to allow specific binding to the protein; e) dissociating the antibodies from the protein, thereby obtaining purified polyclonal antibodies.
- 35. A method of using a protein to prepare a monoclonal antibody comprising:
a) immunizing a animal with a protein of claim 1 under conditions to elicit an antibody response; b) isolating antibody-producing cells from the animal; c) fusing the antibody-producing cells with immortalized cells in culture to form monoclonal antibody producing hybridoma cells; d) culturing the hybridoma cells; and e) isolating from culture monoclonal antibody that specifically binds the protein.
- 36. A method for using a protein to diagnose a cancer comprising:
a) performing an assay to quantify the expression of the protein of claim 1 in a sample; b) comparing the expression of the protein to standards, thereby diagnosing cancer.
- 37. The method of claim 36 wherein the sample is selected from colon, liver, lung, ovary, and prostate.
- 38. The method of claim 36 wherein expression is diagnostic of colon or lung cancer.
- 39. A method for testing a molecule or compound for effectiveness as an agonist comprising:
a) exposing a sample comprising the protein of claim 1 to the molecule or compound, and b) detecting agonist activity in the sample.
- 40. A method for testing a molecule or compound for effectiveness as an antagonist, the method comprising:
a) exposing a sample comprising the protein of claim 1 to a molecule or compound, and b) detecting antagonist activity in the sample.
- 41. An isolated antibody that specifically binds a protein having the amino acid sequence of SEQ ID NO: 1.
- 42. A polyclonal antibody produced by the method of claim 34.
- 43. A monoclonal antibody produced by the method of claim 35.
- 44. A method for using an antibody to detect expression of a protein in a sample, the method comprising:
a) combining the antibody of claim 41 with a sample under conditions which allow the formation of antibody:protein complexes; and b) detecting complex formation, wherein complex formation indicates expression of the protein in the sample.
- 45. The method of claim 44 wherein the sample is from colon, liver, lung, ovary, and prostate.
- 46. The method of claim 44 wherein complex formation is compared with standards and is diagnostic of colon or lung cancer.
- 47. A method for using an antibody to immunopurify a protein comprising:
a) attaching the antibody of claim 41 to a substrate, b) exposing the antibody to a sample containing protein under conditions to allow antibody:protein complexes to form, c) dissociating the protein from the complex, and d) collecting the purified protein.
- 48. A composition comprising an antibody of claim 41 and a labeling moiety.
- 49. A kit comprising the composition of claim 48.
- 50. An array element comprising the antibody of claim 41
- 51. A substrate upon which the antibody of claim 41 is immobilized.
- 52. A composition comprising an antibody of claim 41 and a pharmaceutical agent.
- 53. The composition of claim 52 wherein the composition is lyophilized.
- 54. A method for using a composition to assess efficacy of a molecule or compound, the method comprising:
a) treating a sample containing protein with a molecule or compound; b) contacting the protein in the sample with the composition of claim 48 under conditions for complex formation; c) determining the amount of complex formation; and d) comparing the amount of complex formation in the treated sample with the amount of complex formation in an untreated sample, wherein a difference in complex formation indicates efficacy of the molecule or compound.
- 55. A method for using a composition to assess toxicity of a molecule or compound, the method comprising:
a) treating a sample containing protein with a molecule or compound; b) contacting the protein in the sample with the composition of claim 48 under conditions for complex formation; c) determining the amount of complex formation; and d) comparing the amount of complex formation in the treated sample with the amount of complex formation in an untreated sample, wherein a difference in complex formation indicates toxicity of the molecule or compound.
- 56. A method for treating colon cancer comprising administering to a subject in need of therapeutic intervention the antibody of claim 41.
- 57. A method for treating colon cancer comprising administering to a subject in need of therapeutic intervention the antibody of claim 43.
- 58. A method for treating colon cancer comprising administering to a subject in need of therapeutic intervention the composition of claim 52.
- 59. A method for delivering a therapeutic agent to a cell comprising:
a) attaching the therapeutic agent to a bispecific molecule identified by the method of claim 30; and b) administering the antibody to a subject in need of therapeutic intervention, wherein the antibody specifically binds the protein having the amino acid sequence of SEQ ID NO: 1 thereby delivering the therapeutic agent to the cell.
- 60. The method of claim 59, wherein the cell is an epithelial cell of the colon.
- 61. An agonist that specifically binds the protein of claim 1.
- 62. A composition comprising an agonist of claim 61 and a pharmaceutical carrier.
- 63. An antagonist that specifically binds the protein of claim 1.
- 64. A composition comprising the antagonist of claim 63 and a pharmaceutical carrier.
- 65. A pharmaceutical agent that specifically binds the protein of claim 1
- 66. A composition comprising the pharmaceutical agent of claim 65 and a pharmaceutical carrier.
- 67. A small drug molecule that specifically binds the protein of claim 1.
- 68. A composition comprising the small drug molecule of claim 68 and a pharmaceutical carrier.
- 69. An antisense molecule of 18 to 30 nucleotides in length that specifically binds a portion of a polynucleotide having a nucleic acid sequence of SEQ ID NO: 2 or the complement thereof wherein the antisense molecule inhibits expression of the protein encoded by the polynucleotide.
- 70. The antisense molecule of claim 69 wherein the antisense molecule comprises at least one modified internucleoside linkage.
- 71. The antisense molecule of claim 70 wherein the modified internucleoside linkage is a phosphorothioate linkage.
- 72. The antisense molecule of claim 69 wherein the antisense molecule comprises at least one nucleotide analog.
- 73. The antisense molecule of claim 72 wherein the modified nucleobase is a 5-methylcytosine.
Parent Case Info
[0001] This is a continuation-in-part application of PCT Application No. PCT/US00/07817, filed Mar. 22, 2000, which claims the benefit of Provisional Application Serial No. 60/139,565, filed Jun. 16, 1999.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60139565 |
Jun 1999 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/US00/07817 |
Mar 2000 |
US |
Child |
10187657 |
Jul 2002 |
US |